Clinical Trials Directory

Trials / Unknown

UnknownNCT00394628

AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

A Phase 1b/2a, Multicenter, Open-Label Study of AQ4N in Combination With Radiation Therapy and Temozolomide, to Evaluate the Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Novacea · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.

Conditions

Interventions

TypeNameDescription
DRUGAQ4N
DRUGTemozolomide
PROCEDURERadiotherapy

Timeline

Start date
2006-10-01
First posted
2006-11-01
Last updated
2007-05-30

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00394628. Inclusion in this directory is not an endorsement.

AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme (NCT00394628) · Clinical Trials Directory